<DOC>
	<DOCNO>NCT00818298</DOCNO>
	<brief_summary>Ziprasidone recommend dosed twice daily treatment schizophrenia , base peripheral pharmacokinetics knowledge half life plasma level ( 5-10 hour ) . However , plasma kinetics always mirror occur brain . Antipsychotics high-affinity D2 receptor attach relatively long time bind site even plasma level decline . Based observation , another antipsychotic similar high-affinity D2 receptor , ziprasidone , would also expect keep sufficiently high D2 receptor occupancy even 24 hour last dose . Given &gt; 60 % D2 occupancy require maximize chance therapeutic efficacy , would valuable assess D2 receptor occupancy 24 hour postdose predict therapeutic effect once-daily regimen . In study , measure D2 receptor occupancy 6 , 12 , 24 hour last dose ziprasidone patient schizophrenia . The hypothesis follow : First , base know affinity ziprasidone , dopamine D2 occupancy 24 hour last administer dose 80 mg &gt; 60 % . Second , difference dopamine D2 occupancy scan 6 hour 24 hour less 15 % . Third , difference dopamine D2 occupancy scan 12 hour 24 hour less 10 % . Fourth , ED50 24 hour post dose high 6 12 hour postdose .</brief_summary>
	<brief_title>24-Hour Time Course Striatal Dopamine D2 Receptor Occupancy Ziprasidone : A PET Study</brief_title>
	<detailed_description>PET study demonstrate therapeutic window dopamine D2 receptor occupancy ( 60-80 % ) patient schizophrenia . This observation use predict therapeutic dose range . Ziprasidone recommend dosed twice daily , base knowledge half life plasma level ( 5-10 hour ) . However , plasma kinetics always mirror central kinetics . Antipsychotics high-affinity D2 receptor like risperidone attach relatively long time bind site even plasma level decline . Based observation , another antipsychotic similar high-affinity D2 receptor , ziprasidone , would also expect keep sufficiently high D2 receptor occupancy even 24 hour last dose . Given &gt; 60 % D2 occupancy require maximize chance therapeutic efficacy , would valuable assess D2 receptor occupancy 24 hour postdose predict therapeutic effect once-daily regimen . To date , publish report examine D2 receptor occupancy ziprasidone 24 hour last dose patient schizophrenia . This study provide information 24-hour time course D2 occupancy drug , dissociation peripheral central kinetics drug discuss . The result study also test feasibility daily dose ziprasidone , directly serve guide physician clinical practice . Furthermore , finding study elucidate relationship D2 receptor occupancy long-term outcome . The primary objective determine difference dopamine D2 occupancy ziprasidone expect peak plasma level ( 6 hour ) 12 24 hour postdose . The secondary objective compare ED50 ( plasma level ziprasidone result 50 % maximal receptor occupancy ) 24 hour postdose 6 12 hour postdose . Male female patient age 18-60 year suffer schizophrenia schizoaffective disorder eligible participate study ( Visit 1 ) . Following baseline clinical assessment ( Visit 2 ) , previous antipsychotic discontinue initiate ziprasidone 20mg BID subsequently increase dose 60mg BID ( Visit 2-4 ) . For patient already treat ziprasidone 60 mg BID , titration necessary . If patient low dose , include study treat clinician recommends increase dose 60 mg BID . Participants undergo total 3 raclopride PET scan ( 6 , 12 , 24 hour postdose ) ( Visits 5-7 ) ziprasidone least 14 day . Psychopathology side effect also assess PET visit . MRI scan complete possible ( Visit 8 ) . In subsequent 6-month follow-up phase ( Visit 9-17 ) , participant clinical assessment biweekly first 3 month monthly follow three month . The dose titrate accord clinical response tolerability open-labeled manner maximum dose 80 mg BID .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<criteria>Age 18 60 year . DSMIV/SCID diagnosis schizophrenia , schizoaffective disorder , schizophreniform disorder , delusional disorder , psychotic disorder NOS In outpatient Physicianofrecord 's agreement switch previous antipsychotic ziprasidone due concern tolerability/ineffectiveness/potential side effect previous drug prescribe Incapacity provide consent psychiatric treatment Participation study would result exceed annual radiation dose limit ( 20 mSv ) human subject participate research study . Substance abuse dependence ( within past six month ) Positive urine drug screen Positive serum pregnancy test screen positive urine pregnancy test PET scan History clinically significant physical illness risk factor druginduced arrhythmias secondary QT/QTc interval prolongation Presence risk factor significant electrolyte disturbance , include diuretic therapy , protract diarrhea/vomiting , water intoxication , eat disorder , alcoholism A known history QT prolongation ( include congenital long QT syndrome ) , recent acute myocardial infarction uncompensated heart failure Clinically significant ECG abnormality screen include QT/QTc 450 msec great Being treat dofetilide , sotalol , quinidine , Class Ia III antiarrhythmic , sparfloxacin , gatifloxacin , moxifloxacin , halofantrine , mefloquine , pentamidine , arsenic trioxide , levomethadyl acetate , dolasetron mesylate , probucol , tacrolimus , methadone , clozapine A previous history intolerance hypersensitivity ziprasidone lactose History treatment longacting ( depot ) neuroleptic antipsychotic medication within 6 month Subjects immediate risk commit harm self others Metal implant pacemaker would preclude MRI scan History head trauma result loss consciousness &gt; 30 minute require medical attention Unstable physical illness significant neurological disorder include seizure disorder Size head , neck , body unable fit PET MRI scanner Refusal give consent investigator communicate physician record entire duration study Psychiatric concern raise physicianofrecord regard participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective disorder</keyword>
	<keyword>PET Scan</keyword>
	<keyword>ziprasidone</keyword>
	<keyword>dopamine</keyword>
	<keyword>D2</keyword>
	<keyword>receptor</keyword>
	<keyword>antagonist</keyword>
	<keyword>occupancy</keyword>
	<keyword>dissociation</keyword>
	<keyword>affinity</keyword>
	<keyword>constant</keyword>
	<keyword>Ki</keyword>
	<keyword>ligand</keyword>
	<keyword>raclopride</keyword>
	<keyword>half-life</keyword>
	<keyword>striatal</keyword>
	<keyword>plasma dynamic</keyword>
	<keyword>central dynamic</keyword>
	<keyword>plasma drug level</keyword>
	<keyword>compliance</keyword>
	<keyword>antipsychotic</keyword>
	<keyword>pharmacotherapy</keyword>
	<keyword>twice daily dose</keyword>
	<keyword>BID dose</keyword>
	<keyword>daily dose</keyword>
	<keyword>od dose</keyword>
	<keyword>qd dose</keyword>
	<keyword>dose schedule</keyword>
</DOC>